Literature DB >> 25941611

Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14+ PD-L1+ phenotype in prostate cancer.

Lisa K Spary1, Josephine Salimu1, Jason P Webber1, Aled Clayton1, Malcolm D Mason1, Zsuzsanna Tabi1.   

Abstract

Tumor-associated stromal myofibroblasts are essential for the progression and metastatic spread of solid tumors. Corresponding myeloid cell infiltration into primary tumors is a negative prognostic factor in some malignancies. The aim of this study was to define the exact role of stromal myofibroblasts and stromal factors in early prostate carcinoma (PCa) regulating monocyte infiltration and differentiation into dendritic cells (DCs). Epithelial and stromal primary cultures were generated from PCa biopsies and their purity confirmed. Stromal cells produced significantly more of the (C-C) motif chemokine ligand 2 (CCL2), interleukin 6 (IL-6) and transforming growth factor β (TGFβ) than epithelial cells. Monocyte chemoattraction was predominantly due to stromal-derived factors, mainly CCL2. DCs generated in the presence of stromal (but not epithelial) factors upregulated CD209, but failed to downregulate the monocyte marker CD14 in a signal transducer and activator of transcription 3 (STAT3)-dependent manner. Monocytes exposed to stromal factors did not produce detectable amounts of IL-10, however, upon lipopolysaccharide stimulation, stromal factor generated dendritic cells (sDC) produced significantly more IL-10 and less IL-12 than their conventional DC counterparts. sDC failed to cross-present tumor-antigen to CD8+ T cells and suppressed T-cell proliferation. Most importantly, sDC expressed significantly elevated levels of programmed cell death ligand-1 (PD-L1) in a primarily STAT3 and IL-6-dependent manner. In parallel with our findings in vitro, tumor-infiltrating CD14+ cells in situ were found to express both PD-L1 and CD209, and a higher percentage of tumor-associated CD3+ T cells expressed programmed cell death-1 (PD-1) molecules compared to T cells in blood. These results demonstrate a hitherto undescribed, fundamental contribution of tumor-associated stromal myofibroblasts to the development of an immunosuppressive microenvironment in early PCa.

Entities:  

Keywords:  CCL2; CCL2, (C–C) motif chemokine ligand-2; CFSE, carboxyfluorescein succinimidyl ester; CK, cytokeratin; CM, conditioned media; CXCL, chemokine (C–X–C) motif; DC, dendritic cell; ELISA, enzyme-linked immunosorbent assay; GM-CSF, granulocyte macrophage colony-stimulating factor; HFF, human foreskin fibroblast; HGF, hepatocyte growth factor; I-TAC, interferon-inducible T cell α chemoattractant; IFN, interferon; IL, interleukin; IL-6; IP-10, interferon-γ induced protein 10; LPS, lipopolysaccharide; MIF, macrophage inhibitory factor; PBMC, peripheral blood mononuclear cells; PCaEp, prostate cancer epithelia; PCaSt, prostate cancer stroma; PD-1, programmed cell death-1; PD-L1; PD-L1, programmed cell death ligand-1; RANTES/CCL5, regulated on activation, normal T cell expressed and secreted; SCBM, stromal cell basal media; SDF-1, stromal-derived factor-1; STAT3; STAT3, signal transducer and activator of transcription 3; TGFβ, transforming growth factor β; TIL, tumor infiltrating leukocytes; VEGF, vascular endothelial growth factor; antigen cross-presentation; dendritic cells; immunosuppression; prostate cancer; sDC, DC generated in the presence of 50% PCaSt-CM; tumor microenvironment; tumor stroma; α-SMA, α-smooth muscle actin

Year:  2014        PMID: 25941611      PMCID: PMC4292218          DOI: 10.4161/21624011.2014.955331

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  52 in total

Review 1.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

Review 2.  Tumor escape mechanisms in prostate cancer.

Authors:  Ashley M Miller; Pavel Pisa
Journal:  Cancer Immunol Immunother       Date:  2005-12-16       Impact factor: 6.968

3.  Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.

Authors:  A Hobisch; H Rogatsch; A Hittmair; D Fuchs; G Bartsch; H Klocker; G Bartsch; Z Culig
Journal:  J Pathol       Date:  2000-07       Impact factor: 7.996

4.  Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients.

Authors:  Mercedes Herrera; Alberto Herrera; Gemma Domínguez; Javier Silva; Vanesa García; José M García; Irene Gómez; Beatriz Soldevilla; Concepción Muñoz; Mariano Provencio; Yolanda Campos-Martin; Antonio García de Herreros; Ignacio Casal; Félix Bonilla; Cristina Peña
Journal:  Cancer Sci       Date:  2013-02-21       Impact factor: 6.716

5.  IL-27 production and STAT3-dependent upregulation of B7-H1 mediate immune regulatory functions of liver plasmacytoid dendritic cells.

Authors:  Benjamin M Matta; Giorgio Raimondi; Brian R Rosborough; Tina L Sumpter; Angus W Thomson
Journal:  J Immunol       Date:  2012-04-16       Impact factor: 5.422

6.  The STATus of PD-L1 (B7-H1) on tolerogenic APCs.

Authors:  Tina L Sumpter; Angus W Thomson
Journal:  Eur J Immunol       Date:  2011-02       Impact factor: 5.532

Review 7.  Primary cell cultures as models of prostate cancer development.

Authors:  D M Peehl
Journal:  Endocr Relat Cancer       Date:  2005-03       Impact factor: 5.678

8.  CCL2 is a potent regulator of prostate cancer cell migration and proliferation.

Authors:  Robert D Loberg; LaShon L Day; Jason Harwood; Chi Ying; Lauren N St John; Ryan Giles; Chris K Neeley; Kenneth J Pienta
Journal:  Neoplasia       Date:  2006-07       Impact factor: 5.715

9.  Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression.

Authors:  G Comito; E Giannoni; C P Segura; P Barcellos-de-Souza; M R Raspollini; G Baroni; M Lanciotti; S Serni; P Chiarugi
Journal:  Oncogene       Date:  2013-06-03       Impact factor: 9.867

10.  Immunohistological distribution of 5T4 antigen in normal and malignant tissues.

Authors:  P J Southall; G M Boxer; K D Bagshawe; N Hole; M Bromley; P L Stern
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

View more
  30 in total

1.  Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.

Authors:  Pradeep Tyagi; Saundra S Motley; Tatsuki Koyama; Mahendra Kashyap; Jeffrey Gingrich; Naoki Yoshimura; Jay H Fowke
Journal:  Prostate       Date:  2017-10-27       Impact factor: 4.104

Review 2.  Trial Watch-Oncolytic viruses and cancer therapy.

Authors:  Jonathan Pol; Aitziber Buqué; Fernando Aranda; Norma Bloy; Isabelle Cremer; Alexander Eggermont; Philippe Erbs; Jitka Fucikova; Jérôme Galon; Jean-Marc Limacher; Xavier Preville; Catherine Sautès-Fridman; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-12-08       Impact factor: 8.110

3.  Cross-talk between cancer-initiating cells and immune cells: considerations for combination therapies.

Authors:  Amy S Codd; Saly Al-Taei; Zsuzsanna Tabi
Journal:  Ann Transl Med       Date:  2016-10

4.  Prostaglandin E2-mediated adenosinergic effects on CD14+ cells: Self-amplifying immunosuppression in cancer.

Authors:  Saly Al-Taei; Josephine Salimu; Lisa K Spary; Aled Clayton; Jason F Lester; Zsuzsanna Tabi
Journal:  Oncoimmunology       Date:  2016-12-08       Impact factor: 8.110

Review 5.  Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Authors:  Aitziber Buqué; Norma Bloy; Fernando Aranda; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-03-10       Impact factor: 8.110

Review 6.  The role of macrophage phenotype in regulating the response to radiation therapy.

Authors:  Xiaoshan Shi; Stephen L Shiao
Journal:  Transl Res       Date:  2017-11-20       Impact factor: 7.012

7.  STAT3 inhibition for cancer therapy: Cell-autonomous effects only?

Authors:  Guido Kroemer; Lorenzo Galluzzi; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2016-01-08       Impact factor: 8.110

8.  Small cell lung cancer: Recruitment of macrophages by circulating tumor cells.

Authors:  Gerhard Hamilton; Barbara Rath; Lukas Klameth; Maximilan J Hochmair
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

Review 9.  Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier?

Authors:  Alessandra Modena; Chiara Ciccarese; Roberto Iacovelli; Matteo Brunelli; Rodolfo Montironi; Michelangelo Fiorentino; Giampaolo Tortora; Francesco Massari
Journal:  Oncol Rev       Date:  2016-04-15

10.  Ionizing Radiation Curtails Immunosuppressive Effects From Cancer-Associated Fibroblasts on Dendritic Cells.

Authors:  Rodrigo Berzaghi; Stian Tornaas; Kristin Lode; Turid Hellevik; Inigo Martinez-Zubiaurre
Journal:  Front Immunol       Date:  2021-06-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.